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Abstract
In this chapter, we will explore non-surgical treatments of alopecia. Unlike many other
areas of medicine, pharmacological treatments for alopecia are relatively new. There are
only two treatments which are approved by the Food and Drug Administration (FDA);
the rest are drugs developed for other indications which have gained popular off-label use
to promote hair growth. The reasons for this are many, including the designation of
alopecia by the FDA as a cosmetic disease. This designation has restricted alopecia devel-
opment programs to compounds with virtually no side effects. Unfortunately, it has also
led to off-label use of far more dangerous compounds as alopecia treatments, without the
benefit of controlled trials. There is a growing recognition that alopecia, particularly
alopecia areata and chemotherapy-induced alopecia, are disorders which significantly
alter the quality of life, similar to acne vulgaris and psoriasis, and merit treatment accord-
ingly. There have also been several recent advances in our understanding of the hair cycle,
revealing new targets for developing alopecia therapies. As a result, there is a more robust
slate of programs for developing new pharmacological treatments for alopecia. In this
chapter, we will review current pharmacological treatments for alopecia and selected
treatments under development (i.e., those with significant preclinical or clinical data
which have appeared in the published literature).
Keywords: alopecia, pharmacology, minoxidil, finasteride, glucocorticoid,
diphenylcyclopropenone, DPCP, tofacitinib, ruxolitinib, bimatoprost
1. Introduction
While alopecia is a common problem, the lack of any direct health effects from hair loss has
limited development of pharmacological solutions, mostly due to perceptions by regulatory
authorities that there is no benefit to treatment and therefore there should be no side effects as
well. Current therapies consist of repurposed drugs which were incidentally noted to have
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positive effects on hair regrowth and some therapies designed specifically to regrow hair. Most
are applied topically to reduce the risk of systemic side effects, but this can be an inconvenient
method of application if the hair loss is minimal, and often reduces the efficacy of the treat-
ment. Insurers rarely provide coverage for such therapies. The resulting “benign but minimal
efficacy” therapies have made little impact into the global problem of alopecia, and patients
will often opt for surgical options with greater costs and risks, but promises of markedly
improved results. In this chapter, we review current pharmacological treatments for alopecia
and a selection of those under development (in late preclinical or clinical stage of develop-
ment), including indications, mechanism of action, efficacy, and side effects.
2. Current pharmacological therapies for alopecia
Currently, there are only two Food and Drug Administration (FDA)-approved therapies for
alopecia, minoxidil and finasteride. There are several other therapies commonly used in an off-
label fashion as alopecia therapies.
2.1. Spironolactone
Spironolactone is a diuretic, which acts as an antagonist to aldosterone. Given the structural
similarity of steroid hormones, spironolactone has also some limited androgen-blocking activ-
ity. While spironolactone is not specifically approved for use for hair loss, this weak androgen-
blocking effect has led to the off-label use of spironolactone to minimize hair loss from
polycystic ovarian syndrome (PCOS), usually in conjunction with oral contraceptive therapy
[1]. As it is a weak androgen antagonist, it has not been found to be effective in treating
androgenetic alopecia in males. Spironolactone is an oral medication taken twice per day.
Mechanism of action: spironolactone reduces hair loss by acting as a competitive antagonist at
the androgen receptor. While technically, this could serve to block all forms of androgen-
induced hair loss, the blockade is not potent enough to provide visible effects in androgenetic
alopecia in males. There are observed effects in hair growth patterns, however, in females with
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polycystic ovarian syndrome. Spironolactone can improve growth of scalp hair in this condi-
tion. Spironolactone can also reduce terminal differentiation and hair growth in androgen-
dependent regions of the body (face, arms, back, and abdomen) and thus serve as an effective
treatment for hirsutism.
Side effects: spironolactone’s primary clinical use is as a diuretic, and thus patients taking
spironolactone for alopecia will experience an increased urine output. As spironolactone
antagonizes the effects of aldosterone, potassium levels may become elevated and should be
monitored while on therapy.
Clinical application: spironolactone’s relatively weak effects at the androgen receptor make the
treatment unsuitable as a therapy for androgenetic alopecia. Androgen levels are much lower
in females with polycystic ovarian syndrome, and spironolactone therapy does result in some
noticeable hair growth in some patients with this disorder. However, the overwhelmingly
most prevalent indication for spironolactone therapy is not hair growth, but rather to prevent
regrowth of hair in other androgen-dependent regions of the body as a therapy for hirsutism.
Spironolactone is effective in reducing regrowth of hair in these regions, and, over time, can
reverse terminal differentiation. However, as it does not induce shedding of existing hair, it can
require up to 6 months for full effect and thus is often used as an adjuvant therapy to more
traditional hair-removal techniques (shaving, depilating creams, laser therapy).
2.2. Minoxidil
Minoxidil (Rogaine) was originally marketed by Upjohn as a therapy for hypertension. It was
noted during clinical trials that some male patients with androgenetic alopecia experienced
regrowth of hair during the course of treatment. This led to an effort to repurpose the drug as a
topical treatment for androgenetic alopecia, which was ultimately approved by the FDA for
this indication under the branded name Rogaine. Minoxidil has been found to regrow hair in
40% of patients with androgenetic hair loss after 3–6 months of treatment [2]. Maintenance of
this hair regrowth requires continued therapy. The treatment is most effective in younger
patients with minimal hair loss. It is least effective if there is a broad region of hair loss.
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Mechanism of action: minoxidil has no direct effects on the hair cycle; rather, it stimulates the
vascular bed around the hair follicles and provides a more favorable environment for hair
growth [3]. Specifically, the transition of hair follicles from a resting telogen phase to an active
anagen phase, and maintenance of that anagen phase, depends on interactions between the
bulb of the hair follicle and the vascular bed below. Minoxidil enhances these interactions by
stimulating the proliferation of this vascular bed. Minoxidil does not directly stimulate hair
follicles to transition to anagen phase, nor does it maintain hair follicles in this state. Minoxidil
does not cause hair follicles to transition into terminal, or visibly pigmented hair.
Given this mechanism of action, it is not surprising that minoxidil has minimal effects in the
setting of severe hair loss and has maximal effects when there are still ample normal cycling
terminal hair follicles to support. As the treatment does not directly stimulate hair follicles to
transition to the anagen phase or maintain them in this state, there are also reports that the
resulting hair is thin, hypopigmented, and shorter than normal hair. The responses are not
sustained, and without continued use, the hair is quickly shed.
Side effects: minoxidil was originally developed as an antihypertensive, and oral use could
lower blood pressure and produce symptoms of dizziness, tachycardia, swelling, headache,
and fainting. Topical application minimizes the risk of these systemic side effects. Other
potential side effects include itchiness, rash, and allergic reactions.
While minoxidil is approved for use in androgenetic alopecia, only a small fraction of those
with this disorder actually use minoxidil. The public is very aware of this treatment, likely the
result of heavy marketing at the time of its release in 1988. The low-market penetrance appears
to be the result of continuing costs in the setting of minimal efficacy for those who start
therapy, or perception of minimal effects of treatment for those who do not.
2.3. Finasteride
Finasteride (Propecia) was developed by Merck as a therapy for androgenetic alopecia. The
drug was developed as an oral antiandrogen, which acts by inhibiting the conversion of
testosterone to its more potent form, dihydrotestosterone. The treatment has been shown to
be effective in both androgenetic alopecia males; the treatment of alopecia for polycystic
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ovarian syndrome females appears to be less effective. Finasteride was approved for treatment
of hair loss in the USA in 1997.
Mechanism of action: finasteride acts as an inhibitor of the enzyme 5-alpha reductase, which
converts testosterone to the more potent form dihydrotestosterone. It is extremely effective and
can lower levels by dihydrotestosterone by up to 70% in the bloodstream [4]. However, it does
not inhibit or reduce testosterone levels, and some androgen effects on hair follicles remain
with treatment. Androgens bind to testosterone receptors in stem cells in the bulge of the hair
follicle. The complex binds and depletes intracellular beta-catenin. This inhibits the transition
of the hair follicle from the telogen to anagen phase. By reducing levels of dihydrotestosterone,
the most potent androgen, finasteride, can reverse these changes, allowing hair follicles to
resume normal cycling with effects of visual hair growth. In regions of androgen-dependent
hair growth (face, arms, abdomen, back), finasteride can reduce hair growth.
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Side effects: as finasteride reduces androgen potency, it can lead to sexual dysfunction in
males. These effects include a decreased sexual desire and impotency. These effects may be
temporary as tolerance develops to the medication.
Finasteride is effective in reducing hair loss in males with androgenetic alopecia, resulting in
approximately 30% increases in hair growth [5]. The effects are sustained as long as treatment
is continued, and the hair loss resumes if treatment is stopped. As testosterone is still available
to activate androgen receptors, the response is not complete. In women with polycystic ovar-
ian syndrome, the effects on stimulating hair growth are more modest. The more pronounced
effect on women with this disorder decreases in hirsutism. Similar to minoxidil, the only other
FDA-approved therapy for androgenetic alopecia, finasteride, is used by only a small fraction
of individuals for whom it is potentially indicated. The limited use appears to be related to
limited overall effects on hair growth, requirement for continued therapy to sustain these
gains, and the side effects of sexual dysfunction.
2.4. Oral contraceptives
Oral contraceptives are used in women with polycystic ovarian syndrome primarily as a
means to regulate normal cycles. The treatments can sometimes complicate scalp hair loss
and hirsutism further, as the progestins may have androgenic side effects. The use of oral
contraceptives with reduced androgenic, and even some anti-androgen effects, together with
the suppression of ovarian androgen production, can result in net improvements in scalp hair
growth. Oral contraceptives are designed for use with polycystic ovarian syndrome, including
Yasmin, Yaz, and Ocella (drospirenone/ethinyl estradiol).
Mechanism of action: in normal cycling females, the ovaries produce approximately 50% of
androgen, the rest being produced in the adrenal glands. With PCOS, the anovulatory cycles
reduce ovarian aromatization of androgens to estrogens, resulting in an increased ovarian
androgen production. Oral contraceptives reduce FSH and LH stimulation to the ovaries,
effectively reducing ovarian androgen production (but with adrenal androgen production
unaffected). These net increases in androgen production, together with increases in serum
estrogen levels, can slow or reverse some hyperandrogenic effects in PCOS, including scalp
hair loss, hirsutism, and acne. Estrogen itself can improve scalp hair growth as well, having
direct effects to make the hair thicker and more plusher. While some progestins, that is,
norethindrone, can have some androgenic side effects which limit these effects, oral contracep-
tives designed for use with polycystic ovarian syndrome contain the progestin drospirenone,
which has less androgenic effects. In fact, drospirenone has anti-androgen and anti-
mineralocorticoid effects similar to spironolactone and can aid further in inducing regrowth
of scalp hair and reduction of hirsutism.
Side effects: side effects of oral contraceptives relate mostly to the dose of estrogen. Estrogen
can increase the risk of migraine headaches and deep vein thrombosis. Doses of estrogen in
oral contraceptives designed for use in polycystic ovarian syndrome are lower, such that risks
of these complications, while increased from pre-treatment levels, should not exceed those of
normal cycling females. The progestin drospirenone has an increased risk for deep venous
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thrombosis and blood clots beyond that from the estrogen component of the oral contracep-
tive, which has resulted in warnings to discontinue therapy with surgery [6].
Oral contraceptives are most effective at treating hirsutism and acne from PCOS. Improve-
ments in scalp hair growth can be obtained from a reduced ovarian androgen production,
direct effects of estrogen on hair growth, and with some oral contraceptives, the inhibition of
remaining androgen effect via competitive blocking of the androgen receptor. Oral contracep-
tives do not reduce adrenal androgen production, and as such, the effects on scalp hair growth
are incomplete. Oral contraceptives provide no benefit for other forms of hair loss.
2.5. Glucocorticoid therapy
Glucocorticoid therapy is used for the treatment of autoimmune alopecia, specifically alopecia
areata/totalis/universalis [7]. It has no effect on androgenetic alopecia. Glucocorticoids are
injected subcutaneously directly into the sites of hair loss and can require large number (i.e.,
>80) injections if hair loss is extensive. The response is low, with 30–50% of individuals
showing a response in different patient series. This therapy is not approved by the FDA for
this indication.
Mechanism of action: glucocorticoids are powerful anti-inflammatory components when given
at high doses. Pulsed high-dose oral administration has been shown to be effective [8], but to
minimize systemic side effects, the preferred route of administration is direct injection to the
affected areas. Topical therapy has been found to be less effective [9]. Glucocorticoids do not
directly alter the hair follicles, but the anti-inflammatory effects reduce the autoimmune dis-
ruption of anagen hair follicles which is characteristic of alopecia areata. Response rates are
higher in milder forms of alopecia areata; it is likely that senescence of hair cycling and the
autoimmune response, which is often seen with alopecia totalis and universalis, limits the
efficacy of glucocorticoid therapy in the more severe forms.
Side effects: side effects of glucocorticoid injection result from systemic absorption, which is
minimized but not eliminated with subcutaneous injection. Glucocorticoid administration can
result in increased appetite and weight gain, peripheral muscle wasting, immune suppression,
and osteoporosis. Chronic use can result in skin thinning and adrenal suppression, with the
resulting risk of adrenal crisis with illness. In children, chronic administration can result in
short stature.
Glucocorticoid injections provide a modest hair growth response in alopecia areata with an
overall low risk of systemic side effects. Although not approved by the FDA for this indication,
it is currently the primary therapy for alopecia areata. While side effects are minimized, the
process of receiving multiple scalp injections is difficult, and many patients will decline
glucocorticoid therapy for this reason alone.
2.6. Cyclosporin A
Cyclosporin A is an immune-suppressant drug used primarily to prevent the rejection of
transplanted organs. As an immune suppressant, it has been used for the treatment of
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autoimmune hair loss, specifically in alopecia areata/totalis/universalis. Cyclosporin also has
direct effects to promote the cycling of hair follicles, making it more effective and potentially
complementary to other immune-suppressant therapies. However, cyclosporine has severe
side effects, including an increased risk of serious infections and cancer, hyperglycemia, and
diabetes mellitus. As a result, it is not commonly used as an alopecia therapy.
Mechanism of action: cyclosporin is a power anti-inflammatory agent, which acts by blocking
the transcription of cytokine genes in activated T-cells [10]. Cyclosporin complexes with
cyclophilin and inhibits phosphatase activity of calcineurin, which in turn alters the activation
of NFAT transcription factors. Cyclosporin also blocks antigen recognition pathways by
preventing the activation of the JNK and p38 pathways.
Cyclosporin also acts directly on hair follicles, promoting transition from telogen to anagen
phase and promoting hair growth [11]. This combined mode of therapy makes cyclosporin
ideal as a therapy for alopecia areata. Cyclosporin can be used in combination with glucocor-
ticoid therapy to improve responses [12]. The effects of cyclosporine do not persist if the
therapy is discontinued.
Side effects: side effects from cyclosporine therapy are severe. The immune suppression is
significant and can increase risks of a serious bacterial infection and certain cancers, particu-
larly lymphoma. Monitoring for immune function is recommended on therapy. Cyclosporin
also causes hyperglycemia and can cause diabetes mellitus.
While cyclosporine is theoretically an excellent choice for several forms of hair loss, including
alopecia areata and androgenetic alopecia, the side-effect profile results in very limited use in
clinical settings. As a telling example of this, the patient in the cited case report [12] is now
deceased from pneumonitis.
2.7. Janus kinase (JAK) inhibitors (tofacitinib and ruxolitinib)
Janus kinase inhibitors have been developed primarily as an immune-suppressant therapy
for rheumatoid arthritis. Primary research into the immune-signaling mechanisms for alope-
cia areata revealed that janus kinases are integral to these pathways, and janus kinases
inhibitors have been shown to promote hair growth in alopecia areata. While there are
specific janus kinase inhibitors in development for this indication, there is significant off-
label clinical use of janus kinase inhibitors approved for rheumatoid arthritis for the therapy
of alopecia areata. These agents have the highest reported response rates in the most severe
forms, alopecia totalis and alopecia universalis. An initial report indicated that 75% of
patients responded with at least 50% improvement in hair growth by SALT score after
12 months of therapy, although the study employed a small number of subjects [13]. A larger
series show a more modest 33% of patients with >50% increase in SALT score at 6 months,
which is still superior to other therapies [14]. While JAK inhibitors are effective, they are also
expensive, and the hair growth is not maintained once the treatment is discontinued. They do
not appear to be effective in other forms of alopecia, even to the point that treatment with a
JAK inhibitor revealed unknown androgenetic alopecia in a patient who had alopecia totalis
from early in life [14].
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Mechanism of action: there are three janus kinases, designated JAK-1, JAK2, and JAK3. Their
primary substrates are the various STAT proteins, and they play a critical role in signaling of
immune regulatory factors. JAK-2 has additional clinical importance as the primary signaler
for growth hormone, through linking with STAT-5b; mutations in this STAT protein have been
shown to cause growth hormone resistance and short stature. JAK inhibitors used for applica-
tions of hair growth target JAK-1 and JAK-3, which in turn inhibit STAT3. Inhibition of JAK
pathways inhibits interferon-gamma signaling and inhibits signaling in CD8 + NKG2D+ T-
cells, which have been shown to cause alopecia areata in mouse models [15]. There may also be
some direct effect to promote hair cycling [16].
Side effects: JAK inhibitors have been found to cause elevated liver function studies and
serious bacterial infections in trials for rheumatoid arthritis and psoriasis [17]. Studies in
alopecia areata have not shown these side effects, but the total number of patients in those
studies was much lower. Given the similarities in dosing and duration of treatment, it is likely
that these same side effects will be observed with larger numbers of patients treated.
While JAK inhibitors provide excellent efficacy for hair growth in alopecia areata, the high
cost, latency to effect (6–12 months), lack of durable effect, and side-effect profile are all
potential concerns and limit current clinical use. In addition, JAK inhibitors do not appear to
be effective in other forms of alopecia. Importantly, there are JAK inhibitors under develop-
ment, including topically applied compounds, which may provide a more favorable side-effect
profile and expand the use of these compounds in clinical practice.
2.8. Bimatoprost
Bimatoprost (Latisse) is a prostaglandin analog which was discovered to promote eyelash
growth. It has been approved by the FDA for this indication. Its mechanism of action is to
promote the entry of hair follicles into the anagen phase, and given this, there was promise that
bimatoprost could be used as a more general treatment for various forms of hair loss.
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However, clinical trials have been disappointing, and it appears that the effect is restricted to
the eyelash region.
Bimatoprost was developed for therapy for open-angle glaucoma, under the trade name
Lumigan. However, in clinical trials, it was noted to have a remarkable effect to increase the
growth of eyelashes. It was repurposed for this indication and has been approved by the FDA
and currently marketed for regrowth of eyelashes [18]. It appears to be effective across a
variety of conditions, including chemotherapy, alopecia universalis, and normal individuals
desiring thicker eyelashes [19]. It is applied topically to the eyelash region, and growth of
eyelashes occurs rapidly.
Mechanism of action: bimatoprost is a prostaglandin F2a analog which inhibits prostamids.
There are known links between prostaglandins and hair cycling, including prostaglandin D2
[20], and it appears that bimatoprost grows eyelash hair by transitioning hair follicles into the
anagen phase. This results in rapid regrowth of eyelashes.
Side effects: as bimatoprost is applied topically to eyelash area directly, there are minimal
reports of systemic side effects. Local side effects include conjunctivitis and blurry vision.
There are additional off-target benefits, a decreased intraocular pressure, based on its original
development as a therapy for open- angle glaucoma.
While bimatoprost is very effective at promoting the growth of eyelashes, its effects are
minimal for promoting hair growth outside the eyelash region, with phase 2 trial showing a
similar or only slightly superior efficacy to minoxidil. The reasons for this are not clear, but it
does appear that the interaction between prostaglandins and hair cycling differs based on the
site and/or type of hair follicle. Eyelashes are very different from scalp hair, producing a
thicker shaft that only grows to a specific length; thus, it is not surprising that the regulation
of the hair cycle for these follicles might be different as well. Unfortunately, this limits the
clinical application of bimatoprost to therapy for eyelash shedding.
2.9. Diphenylcyclopropenone (DPCP)
DPCP is a sensitizing agent which is used in the treatment of alopecia areata. The agent is
topically applied weekly and left in place for 6–24 h. Approximately 50% of patients treated
with DPCP respond with regrowth of hair after 6 months of treatment [21]. The response is
durable, with 60% of responders showing a continued hair growth 12 months after receiving
therapy. DPCP is not effective in treating other forms of alopecia.
Mechanism of action: DPCP induces a contact dermatitis, which is thought to redirect the
immune reaction from the hair follicles, allowing regrowth of hair. This includes decreasing
the CD4/CD8 ratio and decreasing levels of interferon-gamma at the site of application. The
patient must first be sensitized to DPCP prior to therapy on the scalp. The response develops
slowly, requiring up to 6 months of treatments. However, once the response develops, it
persists after treatment is discontinued.
Side effects: DPCP treatments are expected to cause a contact dermatitis, with redness and
itching. More severe reactions, including swelling, burning, urticaria, and blistering, can occur.
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Other side effects include fever, arthralgia, more widespread eczema, erythema multiforme,
hyperpigmentation, and hypopigmentation (vitiligo) [22].
DPCP treatments provide response rates in alopecia areata as high as JAK inhibitors, at a lower
cost and with a less severe side-effect profile. However, the contact dermatitis, which is
required for a therapeutic response, is irritating to the patients. Hair growth takes months to
develop, and dermatitis can prevent patients from wearing wigs during the treatment phase.
3. Pharmacological therapies for alopecia under development
There are many therapies for alopecia in various stages of development. A partial list of the
major categories of compounds is subsequently provided, including those with significant
clinical data or established mechanism of action.
3.1. JAK inhibitors
Aclaris is developing JAK inhibitors specifically for therapy for alopecia areata. A-201 is an oral
product, andA-301 is a topical product. Themechanismof action is likely to be similar to tofacitinib
and ruxolitinib, described earlier. Topical application may improve the safety profile by minimiz-
ing systemic exposure and may improve efficacy by delivering higher doses to the skin regions
where hair growth is desired. Aclaris is also developing its JAK inhibitors as therapy for androge-
netic alopecia, although studies with other JAK inhibitors suggest that this will be ineffective.
Concert pharmaceuticals are also developing a JAK inhibitor specifically for therapy for alopecia
areata. CTP-543 is a deuterium-modified analog of ruxolitinib and is believed to have a similar
mechanism of action. Deuteriummay alter the compound’s pharmacokinetics. Leo Pharmaceuti-
cals is developing LEO-124249, a topical JAK inhibitor for the treatment of alopecia areata. Incyte
Corporation is developing a topical preparation of ruxolitinib for the therapy of alopecia areata.
Tigo GmbH is developing interferon-gamma receptor antagonists as a therapy for alopecia
areata. These would act upstream in the same signaling pathway targeted by JAK inhibitors.
3.2. Androgen receptor antagonists
Androscience Corporation is developing an androgen receptor antagonist ASCJ-9 for the
treatment of androgenetic alopecia. The compound is also being developed for acne vulgaris
and wound healing. It is a small molecule which is topically applied and increases degradation
of the androgen receptor. Valeant Pharmaceuticals is developing CB-0301, an androgen recep-
tor antagonist, for the therapy of androgenetic alopecia.
3.3. Vitamin D analogs
Berg L.L.C. is developing BPM 31543, a topically applied analog of 1,25-dihydroxyvitamin D.
It is being developed specifically for the therapy of chemotherapy-induced alopecia. Patients
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with VDR receptor mutations have total body alopecia. However, it is the unoccupied VDR
that is required to activate the hair cycle, apparently by forming complexes with beta-catenin
and LEF-1. There is no hair loss observed in patients with 1-alpha-hydroxylase deficiency, who
make no 1,25-dihydroxyvitamin D. It is therefore unclear how 1,25-dihydroxyvitamin D ana-
logs would prevent hair loss.
3.4. Parathyroid hormone analogs
Parathyroid hormone antagonists can promote hair growth by preventing hair follicle transi-
tion from anagen to catagen phase. ICI Pharmaceuticals was developing parathyroid hormone
antagonists as a therapy for chemotherapy-induced alopecia, but the project was discontinued
because of lack of efficacy. Parathyroid hormone agonists can promote hair growth by stimu-
lating hair follicles to transition from telogen to anagen phase. BiologicsMD is developing
parathyroid hormone agonists as a therapy for several forms of alopecia, including alopecia
areata, androgenetic alopecia, and chemotherapy-induced alopecia.
3.5. TGF-beta receptor antagonists
Auxagen is developing a small molecule compound that suppresses TGF-beta, inhibiting the
transition of hair follicles from anagen to catagen phase. The compound is topically applied.
The company reports that this product is more effective than minoxidil at promoting hair
growth.
3.6. Anti-fibrogenic factor
Birch Biomed Inc. is developing a combination therapy for alopecia areata. Fibrostop 2 is a
kynurenic acid cream which is administered topically. Fibrostop 2 is being developed as a
therapy for psoriasis, alopecia, and scars.
3.7. Neurotrophic activator
BRIM Biotechnology, Inc. is developing a peptide compound that acts to enhance cell prolifer-
ation. The compound, BRM-421, also has ophthalmologic applications and is proceeding to
clinical trials for these indications.
3.8. Stem cell signalers
Histogen is developing a mixture of biologics called hair stimulating complex. This product
includes KGF, VEGF, and follistatin, compounds which signal stem cells in the body and are
critical for hair follicle formation and stimulation of existing hair follicles. The compound
activates stem cells in the bulge and promotes anagen transition of hair follicles.
Rivertown Therapeutics is developing RT1640 for the treatment of androgenetic alopecia.
RT1640 is a mixture of three molecules which is applied topically and stimulates hair growth
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—the compounds are minoxidil, cyclosporin A, and a proprietary compound RT1640. The
compound is applied topically.
3.9. RNAi
There are several companies, including OliX Pharmaceuticals, Quark Pharmaceuticals, and
RXi Pharmaceuticals developing RNAi-based treatments for alopecia. There is little informa-
tion at this time regarding specific compounds or targets.
3.10. Stem cell therapy
RepliCel Life Sciences is developing a method of autologous cell therapy which utilizes dermal
sheath cup cells to treat androgenetic alopecia.
3.11. Histone deacetylases
TetraLogic Pharmaceuticals is developing remetinostat for the therapy of alopecia areata. The
compound is suberohydroxamic acid phenyl ester (SHAPE), which acts by inhibiting histone
deacetylases. It is topically applied and is also being developed for the therapy of cutaneous T-
cell lymphoma and plaque-type psoriasis.
3.12. Interleukin antibodies
AstraZeneca is developing Tralokinumab for the treatment of alopecia areata. Tralokinumab is
a human monoclonal antibody that inhibits interleukin 13, which is an important cytokine for
developing hair loss in alopecia areata. Novartis is developing secukinumab for the treatment
of alopecia areata. Secukinumab is a human monoclonal antibody that inhibits interleukin
17A, which is also an important cytokine for developing hair loss in alopecia areata.
Secukinumab is also being developed for severe plaque psoriasis, psoriatic arthritis, rheuma-
toid arthritis, ankylosing spondylitis, and uveitis.
3.13. Stem cell therapy
Stem cells play a critical role in hair follicle regeneration and in the hair cycle. Stem cells are
located in the bulge region of the hair follicle, and under control of Wnt signaling, they
proliferate and migrate down the hair follicle shaft to transform the follicle into the anagen
phase. Efforts have been made to treat various forms of hair loss, including androgenetic
alopecia and alopecia areata, with stem cell injections. There are reports of improvements of
hair growth with these techniques [23], and there are some hair growth centers which utilize
these techniques.
3.14. Platelet-rich plasma therapy
Rather than infusing stem cells, one can also infuse plasma, which is rich in factors which can
stimulate stem cells. Platelet-rich plasma (PRP) is a plasma concentrate which has been used
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for regenerative purposes in a variety of settings, including wound healing, cartilage damage,
and scarring. Injection with autologous PRP has been shown to increase hair growth in
androgenetic alopecia [24], presumably by stimulating stem cells in the bulge region to regen-
erate hair follicles and induce anagen transition.
3.15. Adipose-derived stromal vascular fraction (SVF)
Adipose-derived stem cells, also referred to as stromal vascular fraction (SVF), are another
potential source of stem cells and/or stem cell-stimulatory factors which can be used to pro-
mote hair growth. This was discovered incidentally by observing effects after the transplant of
autologous fat on hair growth. Early trials of injection of SVF show photographic evidence of
hair regrowth and quantifiable (23.3%) increase in hair counts [25] in patients with androge-
netic alopecia.
4. Conclusions
While there are only two FDA-approved pharmacological treatments for alopecia, there are a
wide variety of compounds used off-label and an even larger number of compounds in various
stages of development. This reflects a large and growing interest in developing effective
therapies for alopecia. However, most of these compounds in clinical use suffer from the same
limitations, which are poor efficacy and lack of durable effect. Several, particularly the immune
modulators, are also hampered by being associated with severe side effects. Development
programs have been hindered by the designation of alopecia as a cosmetic disease, which
restricts programs to compounds with virtually no side effects. Advances in basic science have
led to an improved understanding of the hair cycle, revealing new targets for drug develop-
ment. As a result, there is a robust slate of development programs, which show promise for the
development of more effective treatments for alopecia in the future.
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